Antengene

Tokyo, Japan, August 25, 2026 Astellas Pharma Inc. announced that the first patient has been dosed in a Phase...

Shanghai and Hong Kong, China, August 25, 2026 Antengene Corporation Limited announced that the Phase I ATTRACT clinical study...

LONDON, United Kingdom, July 13, 2026 The Alzheimer’s Association has announced the launch of the PROTECT-Cog Study (Prevention of...

SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...

SHANGHAI, China, June 22, 2026 CureGene Pharmaceutical has announced the successful dosing of the first participant in the U.S....

BOSTON, Singapore and Hong Kong, June 22, 2026 Antengene Corporation Limited has announced a landmark strategic licensing agreement with...

Tokyo, Japan – June 9, 2026 Kyowa Kirin Co., Ltd. has published its Integrated Report 2025, outlining the company’s...

SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...

SHANGHAI and HONG KONG, China, June 8, 2026 Antengene Corporation Limited announced the presentation of the first preclinical data...

LONDON, United Kingdom, June 3, 2026 Johnson & Johnson has announced positive late-breaking results from its Phase 2 JASMINE...